10 Italian life sciences startups wrap U.S. program in Boston

Ten Italian biotech and pharma startups are ending a four-week U.S. program in Boston on Nov. 12 after visits, investor meetings and Demo Days in San Diego and Cambridge. The cohort is pitching cancer therapies, AI health tools and circular-economy biomaterials as it prepares for U.S. expansion.

Why it matters: - The 10 startups are trying to break into one of the world’s most important life sciences markets. - The program gives the companies exposure to researchers, investors and potential commercial partners in San Diego and Boston. - The cohort includes therapies, digital health tools and sustainable biomaterials with possible U.S. market relevance.

What happened: - The Biotech & Pharma cohort of the Italian Trade Agency’s Global Startup Program spent three weeks in San Diego and moved to Boston for its final U.S. week. - The Boston leg runs through Nov. 13 and ends with a final Demo Day on Nov. 12. - The cohort is part of the seventh edition of the Global Startup Program, which includes six industry-specific cohorts across international innovation hubs. - The Italian Trade Agency’s Los Angeles office coordinates the cohort with the Consulate General of Italy in Los Angeles and Elpis Labs.

The details: - The four-week program began with online training from Sept. 28 to Oct. 9. - In San Diego, the startups visited BioLabs in the Torrey Pines biotech cluster, UC San Diego and the Salk Institute. - The cohort also met life sciences investors and industry experts, including representatives of Avalon Ventures. - The startups presented their companies at a Demo Day in San Diego on Nov. 5. - In Boston, the group is visiting LabCentral in Kendall Square and the Longwood Medical Area. - The Boston schedule also includes meetings with investors and potential industry partners. - The program covers FDA regulatory pathways, intellectual property, fundraising and U.S. commercialization strategy. - The initiative aims to strengthen the startups’ technical, operational and financial capabilities for international expansion.

Between the lines: - The cohort reflects where Italian innovation is headed: drug discovery, AI-enabled healthcare operations, privacy-focused clinical data systems and circular-economy biotech. - The mix of companies suggests the Italian Trade Agency is positioning startups for both scientific validation and U.S. business development. - The program also signals how European startups are using U.S. biotech hubs as a shortcut to market access and investor relationships.

The startups: - BrightMol Biotech developed a platform that identifies and validates promising drug molecules directly in living cells. - Kiran Biotech developed a patented platform designed to retain therapeutic agents, including radiopharmaceuticals and antibodies, locally within tissues to make treatments more targeted and reduce side effects. - Thera65 is developing a therapeutic approach to overcome drug resistance in certain solid tumors by selectively degrading a tumor-specific protein. - Nemira develops digital tools to improve communication and coordination among families, caregivers and healthcare professionals for ongoing elder care, with an initial focus on dementia and privacy-focused AI capabilities. - Ninacare offers an AI-powered platform that automates recruitment and human resources management for hospitals and care facilities. - QubiTale provides a technology platform that lets hospitals use patient data for research while protecting privacy. - V-Apps.cloud offers software that integrates quality management, safety, training and regulatory compliance for highly regulated industries, including pharmaceuticals and medical devices, through modules and AI agents. - Alma Serum develops dissolvable cosmetic membranes made from keratin nanofibers that release active ingredients directly onto the skin. - AlphaFood develops food and protein products made with cricket flour, plus vertical farming systems and software for monitoring, traceability and standardized production. - Blueat, developed by Mariscadoras, turns invasive blue crabs into food products and uses processing byproducts to create sustainable biomaterials through a circular-economy model.

What’s next: - The cohort’s final Demo Day in Boston on Nov. 12 will give the startups another chance to pitch to East Coast investors and industry partners. - The startups are expected to use the program’s contacts and feedback to refine U.S. market-entry plans. - The Global Startup Program continues to support international expansion through mentoring, investor meetings, business development and networking.

The bottom line: - Italy’s biotech pipeline is being stress-tested in Boston, with the goal of turning promising science into investable U.S. businesses.